does ipamorelin increase cortisol (RUO) | Selective GHS-R1a Agonist Ipamorelin - Research Peptide -

Conclusion Ipamorelin represents a highly selective growth hormone secretagogue with receptor specificity that enables effective GH stimulation without substantial activation of other endocrine pathways

Conclusion The preclinical record for ipamorelin shows a consistent selectivity profile at the GHS-R1a receptor, with animal and in vitro data supporting a GH-focused pituitary output that avoids the corticotroph and lactotroph co-activation observed with earlier GHRPs

This is the most frequently reported effect and is inherent to GHRP-6's mechanism Mild water retention and peripheral edema, particularly during the first 2 to 4 weeks Transient flushing, warmth, or dizziness immediately post-injection Injection site reactions (redness, minor swelling) Less Common: Tingling or numbness in the extremities (hands and feet), related to GH-mediated fluid shifts Head rush or lightheadedness shortly after administration Drowsiness, particularly with evening doses Dose-Dependent (above saturation dose): Elevated cortisol via ACTH stimulation

Analytical testing for this batch was performed by Liquilabs s.r.o